Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables: 2009-2025

Historic Receivables for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to $26.8 million.

  • Gyre Therapeutics' Receivables rose 28.61% to $26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.6 million, marking a year-over-year increase of 41.78%. This contributed to the annual value of $28.9 million for FY2024, which is 85.98% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Receivables is $26.8 million, which was up 5.69% from $25.4 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Receivables high stood at $28.9 million for Q4 2024, and its period low was $564,000 during Q1 2022.
  • For the 3-year period, Gyre Therapeutics' Receivables averaged around $20.2 million, with its median value being $20.8 million (2024).
  • Its Receivables has fluctuated over the past 5 years, first slumped by 45.13% in 2021, then surged by 842.57% in 2022.
  • Gyre Therapeutics' Receivables (Quarterly) stood at $1.8 million in 2021, then skyrocketed by 842.57% to $17.1 million in 2022, then declined by 9.24% to $15.6 million in 2023, then soared by 85.98% to $28.9 million in 2024, then grew by 28.61% to $26.8 million in 2025.
  • Its last three reported values are $26.8 million in Q3 2025, $25.4 million for Q2 2025, and $22.5 million during Q1 2025.